The development of novel oligosaccharides from dairy lactose for improved infant nutrition. This project will develop new milk sugars to enhance nutrition for the 46 per cent of infants who receive formula. It will support rural and regional dairy communities and manufacturers increasing innovation, potentially generating six million dollars in new sales per annum, increasing returns to farmers and promoting regional employment and spending.
Enzymatic synthesis, microencapsulation and biological evaluation of a new class of omega-3 derived functional food ingredients. Inflammatory mediated diseases such as cardiovascular disease, type-2 diabetes, metabolic syndrome and Alzheimer's disease are major causes of death in Australia. Rates of these diseases are rising over time, partly due to poor diet including low consumption levels of healthy omega-3 fatty acids from fish. This project aims to develop healthy food ingredients from natu ....Enzymatic synthesis, microencapsulation and biological evaluation of a new class of omega-3 derived functional food ingredients. Inflammatory mediated diseases such as cardiovascular disease, type-2 diabetes, metabolic syndrome and Alzheimer's disease are major causes of death in Australia. Rates of these diseases are rising over time, partly due to poor diet including low consumption levels of healthy omega-3 fatty acids from fish. This project aims to develop healthy food ingredients from naturally occurring omega-3 fatty acid derivatives that are more stable to oxidation and more biologically active than fish derived omega-3 fatty acids. The development of these omega-3 derivatives as functional food ingredients could provide an additional strategy for helping to prevent the rapid increase in inflammatory mediated diseases in the Australian population.Read moreRead less
Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in preg ....Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in pregnant women, and to further develop such antibodies for therapy. Identification of mothers at risk of FMAIT and the development of a specific therapy are vital to the management and prevention of this serious condition.Read moreRead less
Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innov ....Industrial biotechnology for improved manufacture of medicinal alkaloids. Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innovative bioreactor to achieve high yield. It will research industrial biotransformations, providing a greener and cheaper process for increased global access to Codeine. Australian opiate manufacturing is expected to benefit from value adding and increased flexibility introduced by a biotechnology approach.Read moreRead less
Novel chemoenzymatic synthesis and bioconjugation of peptides and proteins. This project aims to solve the critical difficulty of producing the complex peptide insulin and related insulin-like peptides (INSLs) and their analogues. The project will use unique, recyclable enzymes which ligate smaller peptide segments with extraordinary site and substrate selectivity. The expected outcome of the project is novel, cheaper and scalable, enzyme-mediated engineering of this critical class of peptides a ....Novel chemoenzymatic synthesis and bioconjugation of peptides and proteins. This project aims to solve the critical difficulty of producing the complex peptide insulin and related insulin-like peptides (INSLs) and their analogues. The project will use unique, recyclable enzymes which ligate smaller peptide segments with extraordinary site and substrate selectivity. The expected outcome of the project is novel, cheaper and scalable, enzyme-mediated engineering of this critical class of peptides as biological probes and potential therapeutic agents.Read moreRead less
Industrial biotechnology for the manufacture of alkaloid pharmaceuticals. Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechn ....Industrial biotechnology for the manufacture of alkaloid pharmaceuticals. Drugs that treat opioid dependence and overdose are increasingly needed but their manufacture is difficult, inefficient and expensive. This project aims to develop enzymatic N-demethylation as a simpler and more sustainable approach to the manufacture and modification of opioid antagonists, alkaloids and other drug targets. It will increase our understanding of enzymatic N-demethylation and address engineering and biotechnology challenges to improve yield and product isolation and concentration. Improvements in drug manufacturing processes will assist drug affected communities and industry will benefit from value adding, greater market share and flexibility, increased innovation and de-risked processes and new products. Read moreRead less
Novel enzymatic processing methods and stabilization technologies for omega-3 oils. New and existing lipases will be applied to the concentration of omega-3 lipids from fish and algal oils. The primary aim of this project is to replace current chemical processes and high temperature distillation with milder enzymatic methods, providing high quality omega-3 concentrates for food and pharmaceutical purposes. The project aims to develop new immobilisation technology to enable multiple re-use of lip ....Novel enzymatic processing methods and stabilization technologies for omega-3 oils. New and existing lipases will be applied to the concentration of omega-3 lipids from fish and algal oils. The primary aim of this project is to replace current chemical processes and high temperature distillation with milder enzymatic methods, providing high quality omega-3 concentrates for food and pharmaceutical purposes. The project aims to develop new immobilisation technology to enable multiple re-use of lipases for the cost effective production of omega-3 concentrates and to apply new microencapsulation strategies to the stabilisation of omega-3 concentrates, enabling the delivery of omega-3s and other bioactive ingredients to a range of food and beverage products.Read moreRead less